Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Glucagon is a pancreatic hormone that plays a crucial role in regulating glucose and whole-body energy metabolism. In individuals with diabetes, the pancreatic alpha cells that produce glucagon are ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not ...

Eli Lilly is developing new weight-loss drugs, including a daily pill, that are expected to set up years of blockbuster sales for the company. Novo Nordisk has a hazier path forward.

The Centers for Medicare & Medicaid Services on Friday rejected a Biden administration proposal to expand Medicare coverage of weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk's ...

Novo Nordisk’s pipeline includes clinical-stage drugs that hit two targets. UBT251 gives the Danish pharmaceutical giant a once-weekly injection that hits three: GLP-1, GIP, and glucagon.

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.